8-K: Cocrystal Pharma Reports Third Quarter 2024 Results and Provides Antiviral Program Updates

Cocrystal Pharma announced its third quarter 2024 financial results and provided updates on its antiviral drug development programs, including upcoming clinical trial milestones.

Summary

• Cocrystal Pharma reported a net loss of $4.9 million, or $0.49 per share, for the third quarter of 2024, compared to a net loss of $4.2 million, or $0.41 per share, for the same period in 2023.
• Research and development expenses decreased to $3.2 million in Q3 2024 from $4.2 million in Q3 2023, primarily due to lower clinical study expenses.
• General and administrative expenses remained relatively stable at $1.8 million for both Q3 2024 and Q3 2023.
• For the first nine months of 2024, the net loss was $14.2 million, or $1.40 per share, compared to a net loss of $13.5 million, or $1.43 per share, for the same period in 2023.
• The company's cash balance was $13.0 million as of September 30, 2024, down from $26.4 million at the end of 2023.
• Net cash used in operating activities for the first nine months of 2024 was $13.3 million, compared to $11.3 million for the same period in 2023.
• Cocrystal expects to report topline results from the Phase 2a influenza A challenge study with CC-42344 before the end of 2024.
• Topline results from the Phase 1 pan-norovirus/pan-coronavirus study with CDI-988 are expected in late 2024 or early 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant clinical progress and sufficient cash runway, but also acknowledges financial losses and risks associated with drug development.

Positives

• The company has made significant clinical progress this year and is on track for an active 2025.
• Cocrystal's cash position is expected to fund planned development programs for the next 12 months.
• The company's drug discovery platform is designed to develop broad-spectrum antivirals that are effective against viral mutations.
• CC-42344 has shown promising in vitro activity against various influenza A strains, including resistant ones.
• CDI-988 has demonstrated pan-viral activity against multiple norovirus strains and coronaviruses.
• The company has completed enrollment in the Phase 2a human challenge study for CC-42344.
• The multiple-ascending dose portion of the Phase 1 study for CDI-988 is underway.

Negatives

• The company reported a net loss of $4.9 million for the third quarter of 2024, which is higher than the $4.2 million loss in the same period of 2023.
• The company's cash balance decreased from $26.4 million at the end of 2023 to $13.0 million as of September 30, 2024.
• Net cash used in operating activities increased to $13.3 million for the first nine months of 2024, compared to $11.3 million for the same period in 2023.
• The company's net loss per share increased from $0.41 in Q3 2023 to $0.49 in Q3 2024.

Risks

• The company faces risks and uncertainties arising from future inflation, potential future increases in interest rates, uncertainty in the financial markets, the possibility of a recession, and geopolitical conflict.
• Manufacturing and research delays may arise from raw materials and labor shortages, supply chain disruptions, and other business interruptions.
• There are risks associated with the ability of CROs to recruit volunteers for and proceed with clinical studies.
• The company's technology and software may not perform as expected.
• Financial difficulties experienced by certain partners could impact the company.
• The results of current and future preclinical and clinical studies are uncertain.
• There are general risks arising from clinical studies and the receipt of regulatory approvals.
• Regulatory changes, including potential downward pressure on government spending on healthcare, could impact the company.
• Potential mutations in targeted viruses may result in variants that are resistant to the company's product candidates.

Future Outlook

The company expects to report topline results from the Phase 2a influenza A challenge study with CC-42344 before the end of 2024 and topline results from the Phase 1 pan-norovirus/pan-coronavirus study with CDI-988 in late 2024 or early 2025. Cocrystal anticipates an active 2025 with the advancement of its planned development programs.

Management Comments

• Sam Lee, Ph.D., President and co-CEO of Cocrystal, stated that the coming months are critically important as they expect to report topline results from two ongoing clinical studies.
• James Martin, CFO and co-CEO of Cocrystal, stated that the company's cash is expected to be sufficient to fund the advancement of planned development programs through the coming 12 months.

Industry Context

The announcement highlights Cocrystal's efforts in developing antiviral treatments for influenza, norovirus, and coronaviruses, which are significant global health threats. The company's focus on broad-spectrum antivirals and its structure-based drug discovery platform positions it to address the challenges of viral mutations and resistance to existing treatments. The company is operating in a competitive market with other companies also developing antiviral treatments.

Comparison to Industry Standards

• Cocrystal's approach of targeting highly conserved regions of viral enzymes aligns with the industry trend of developing broad-spectrum antivirals to combat viral mutations.
• The company's focus on norovirus is notable, as there are currently no approved vaccines or antivirals for this highly contagious virus, representing a significant unmet medical need.
• The company's clinical trial timelines are consistent with industry standards for early-stage drug development, with topline results expected within the next few months.
• The company's cash burn rate is typical for a clinical-stage biotech company, and the company's statement that it has sufficient cash to fund operations for the next 12 months is a positive sign.
• Companies like Gilead Sciences, Roche, and Pfizer are major players in the antiviral market, and Cocrystal will need to demonstrate strong clinical results to compete effectively.

Related Party Transactions

• The company has operating lease right-of-use assets and liabilities with a related party.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the progress of its clinical trials.
• Employees are impacted by the company's financial stability and the success of its drug development programs.
• Customers (potential patients) are impacted by the development of new antiviral treatments.
• Suppliers and creditors are impacted by the company's financial health and ability to meet its obligations.

Next Steps

• The company expects to report topline results from the Phase 2a influenza A challenge study with CC-42344 before the end of 2024.
• The company expects to report topline results from the Phase 1 pan-norovirus/pan-coronavirus study with CDI-988 in late 2024 or early 2025.
• The company plans to file an IND application in 2025 to conduct a late-stage study in the U.S. for CC-42344.

Key Dates

Keywords

antiviral, influenza, norovirus, coronavirus, clinical trials, drug development, CC-42344, CDI-988, biotechnology, pharmaceuticals